The lead author of a recent publication from the Memory and Aging Project discussed the data and what impact flavonol intake might have on the risk of developing Alzheimer disease dementia.
This additional application, supported by data from the GWPCARE6 trial, seeks to expand the indication of cannabidiol to include seizures associated with tuberous sclerosis complex.
The software, developed by Qynapse, provides analysis of brain MRI markers in diseases such as Alzheimer disease, Parkinson disease, and multiple sclerosis.
SK Life Science’s sodium channel antagonist cenobamate was approved based on data from pivotal trials in nearly 2000 patients in which it reduced the median number of seizures per 28 days.
The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.
The 2019 update to the 2018 guidelines clarifies prior recommendations and takes into consideration new clinical trial data to offer a comprehensive guide for treatment, from symptom onset through 2 weeks after acute ischemic stroke.
Cerevel Therapeutics’ highly selective dopamine D1/D5 agonist showed significant reductions in UPDRS-III scores for those with early-stage Parkinson disease and is planned to enter phase 3 in 2020.
After showing significant benefits in delayed disease progression in patients with secondary progressive MS, new data suggests siponimod can delay the time to wheelchair dependence by 4 years.
The guidelines recommend that patients with MS receive their recommended vaccines, including that for yearly influenza. Additionally, they noted that no evidence exists that suggests vaccination increases the risk of MS exacerbation.
After being approved in Japan in 2013, the selective adenosine A 2A receptor antagonist was given the OK as an add-on to levodopa/carbidopa treatment in adults with Parkinson disease.